Occudo Quantitative Strategies LP Tricida, Inc. Transaction History

Occudo Quantitative Strategies LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$8.51 - $13.6 $113,795 - $181,859	13,372 Added 20.89%	77,388 $811,000
Q2 2022 Aug 15, 2022	BUY	$7.31 - $11.85 $198,137 - $321,194	27,105 Added 73.43%	64,016 $620,000
Q1 2022 May 16, 2022	BUY	$7.35 - $10.63 $169,035 - $244,468	22,998 Added 165.3%	36,911 $303,000
Q4 2021 Feb 14, 2022	SELL	$4.19 - $9.56 $21,490 - $49,033	-5,129 Reduced 26.94%	13,913 $133,000
Q3 2021 Nov 15, 2021	SELL	$3.56 - $4.64 $31,826 - $41,481	-8,940 Reduced 31.95%	19,042 $88,000
Q2 2021 Aug 16, 2021	SELL	$3.95 - $5.41 $199,581 - $273,351	-50,527 Reduced 64.36%	27,982 $121,000
Q1 2021 May 14, 2021	BUY	$4.52 - $7.8 $86,729 - $149,666	19,188 Added 32.35%	78,509 $415,000
Q4 2020 Feb 16, 2021	BUY	$4.37 - $9.46 $259,232 - $561,176	59,321 New	59,321 $418,000

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Occudo Quantitative Strategies LP, based on Form 13F filings with the SEC.

Stay updated on Occudo Quantitative Strategies LP with notifications on news.